SANOFI US SERVICES INC. for SANOFI US SERVICES INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 18, 2008 | $1,220,000 | Replaced |
| 2nd Quarter - Amendment | Dec 18, 2008 | $1,480,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Miscellaneous tariffs legislation
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| ANN TAYLOR | — |
Taxation/Internal Revenue Code TAX
Corporate tax and tax treaty issues; extension of the US R&D jobs tax credit, including such provisions in HR1712 "Research and Development Tax Credit Act of 2007," HR2138 "Investment in America Act of 2007," S41 "Research Competitiveness Act of 2007" and S2209 "Research Credit Improvement Act of 2007"
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN TAYLOR | — |
Health Issues HCR
Deep Vein Thrombosis (DVT) awareness and quality of care; DVT Call To Action; provisions related to transition rules for follow-on biologics in S 623 "Access to Life-Saving Medicine Act", HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; awareness of the Together Rx Access program; awareness of the Access to Medicines Program; HR 1585 and S567, "National Defense Authorization Act for FY2008"; HR 4896 "National Defense Authorization Act for FY2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System.; issues related to the 340B federal drug pricing program
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| MARK COIN | — |
| EDWARD GREISSING | — |
| RICHARD M HODGE | — |
| SAIRA SULTAN | — |
Medicare/Medicaid MMM
compendia coverage of Medicare Part B drugs, including such related provisions in HR 3162 "Children's Health and Medicare Protection Act of 2007"
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SAIRA SULTAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.